Overview

Spinal Muscular Atrophy Treatment Market is poised to register a CAGR of 28.9% during the forecast period 2022 to 2028. 

Rising awareness pertaining to spinal muscular atrophy, soaring initiatives from improving treatment alternatives for rare diseases are some of the crucial factors contributing to the growth of the market. For instance, the U.S FDA awarded an orphan drug license to the collaborative program of SMA Foundation, PTC Therapeutics and Roche named RG7916 for treating spinal muscular atrophy. Furthermore, the growing initiatives implemented by different non-profit and public organizations for creating awareness pertaining to SMA has boosted the spinal muscular atrophy treatment market growth. Additionally, the National Institute for Care and Health Excellence in January 2018, summoned Biogen for submitting a tech appraisal for Spinraza. NHs and NICE have agreed for a long-term plan regarding Biogen’s Spinraza. Such a wide range of products for treating SMA has propelled the proliferation of the market. 

Market Segmentation:

By Treatment
•    Drugs
•    Gene Therapy

By Route of Administration
•    Oral
•    Intrathecal

By Disease Type 
•    Type 1
•    Type 2
•    Type 3
•    Type 4

By Region
•    North America
•    Europe
•    Asia-Pacific
•    Latin America
•    Middle East and Africa

The market is classified into treatment, route of administration, disease type and region. The treatment segment is fragmented into gene therapy and drugs. The gene therapy segment is anticipated to hold the largest spinal muscular atrophy treatment market share as it is a viable option than drugs. Additionally, Spinraza is the only drug that received an FDA approval for SMA treatment in recent times which is why it is expected that the drugs segment is predicted to grow at a substantial rate during the forecast period. The route of administration segment is classified into oral and intrathecal. The intrathecal segment is anticipated to lead the market as drugs like Spinraza are provided intrathecally. Additionally, no new drugs are expected to be launched till the end of 2021 which shall maintain its market dominance.
The disease type segment is categorised into type 1, type 2, type 3 and type 4. The type 1 segment is estimated to lead the market owing to its rising prevalence. Furthermore, companies are emphasizing on developing drugs for treating type 1 SMA and this shall boost the segment growth. Similarly, there have been significant progress in the development of novel therapies. For instance, AveXis Inc. have developed a gene therapy, AVXS-101, which has been tested clinically for safety evaluations. Similarly, Novartis AG’s LMI07 also focusses on treating type 1 SMA. 

Regional Analysis:

The North America region is predicted to dominate the market as the Unites States market generates maximum revenue amongst all regions. Furthermore, crucial players like Biogen are in the region as they have developed important drugs like Spinraza. Moreover, there has been a rise in the number of initiatives conducted by private and public bodies for creating awareness coupled with growing investments in research and development activities related to spinal muscular atrophy.

Competitive Landscape:                            

Some of the major players of the market are Biogen, Ionis Pharmaceuticals Inc., F. Hoffmann La Roche Ltd., Avenis Inc., Novartis AG, Cytokinetics Inc.

FutureWise Key Takeaways:

•    Growth prospects
•    SWOT analysis 
•    Key market trends 
•    Key data-points affecting market growth

Objectives of the Study:

•    To provide with an exhaustive analysis on the global spinal muscular atrophy treatment market by treatment, by route of administration, by disease type and by region
•    To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
•    To evaluate and forecast micro-markets and the overall market 
•    To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa
•    To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:

•    We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
•    The customization Mobility Care offered are free of charge with purchase of any license of the report
•    You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
          1.1 Objectives of the Study 
          1.2 Market Definition 
          1.3 Market Scope 
                1.3.1 Years Considered for the Study
                1.3.2 Market Covered
          1.4 Currency
          1.5 Limitations 
          1.6 Stakeholders 

2. Research Methodology 
          2.1 Research Data 
                 2.1.1 Secondary Data
                         2.1.1.1 Key Data from Secondary Sources
                 2.1.2 Primary Data
                         2.1.2.1 Key Data from Primary Sources
          2.2 Market Size Estimation 
          2.3 Market Breakdown and Data Triangulation 
          2.4 Assumptions for the Study  

3. Executive Summary
          3.1 Market Outlook
          3.2 Segment Outlook
          3.3 Competitive Insights

4. Spinal Muscular Atrophy Treatment Market Variables, Trends & Scope
          4.1 Market Lineage Outlook
          4.2 Penetration and Growth Prospect Mapping
          4.3 Industry Value Chain Analysis
          4.4 Cost Analysis Breakdown
          4.5 Technology Overview
          4.6 Regulatory Framework on Country Level
                4.6.1 Reimbursement Framework    
                4.6.2 Standards and Compliances

5. Market Overview
          5.1 Market Dynamics
                5.1.1 Market Driver Analysis
                5.1.2 Market Restraint Analysis
                5.1.3 Industry Challenges                   

6. Spinal Muscular Atrophy Treatment Market Analysis tools                       
          6.1 Industry Analysis - Porter’s
                     6.1.1 Supplier Power
                     6.1.2 Buyer Power
                     6.1.3 Substitution Threat
                     6.1.4 Threat from new entrants
                     6.1.5 Competitive Rivalry                  
          6.2 Pestel Analysis
                     6.2.1 Political Landscape
                     6.2.2 Environmental Landscape
                     6.2.3 Social landscape
                     6.2.4 Technology landscape
                     6.2.5 Legal Landscape

7. Spinal Muscular Atrophy Treatment Market, By Treatment Historical Analysis 2016 to 2020 and Forecast 2022-2028 (USD million)
          7.1 Drugs
          7.2 Gene Therapy

8. Spinal Muscular Atrophy Treatment Market, By Route of Administration Historical Analysis 2016 to 2020 and Forecast 2022-2028 (USD million)
          8.1 Oral
          8.2 Intrathecal

9. Spinal Muscular Atrophy Treatment Market, By Disease Type Historical Analysis 2016 to 2020 and Forecast 2022-2028 (USD million)
          9.1 Type 1
          9.2 Type 2
          9.3 Type 3
          9.4 Type 4                                                   

10. North America Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
          10.1. Introduction
          10.2. Historical Market Size (USD Mn) Analysis By Country, 2016-2020
                10.2.1. U.S.
                10.2.2. Canada
                10.2.3. Mexico
                10.2.4 Rest of North America
          10.3 Market Size (USD Mn) Forecast for North America 2022-2028

11. Latin America Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
          11.1. Introduction
          11.2. Regional Market Trends
          11.3. Historical Market Size (US$ Mn) Analysis By Country, 2016-2020
                11.3.1. Brazil
                11.3.2. Uruguay
                11.3.3 Argentina
                11.3.4. Rest of Latin America
          11.4 Market Size (US$ Mn) Forecast for Latin America 2022-2028

12. Europe Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
          12.1. Introduction
          12.2. Historical Market Size (US$ Mn) Analysis By Country, 2016-2020
                12.2.1. Germany
                12.2.2. U.K
                12.2.3. France
                12.2.4. Italy
                12.2.5 Switzerland
                12.2.6. Spain
                12.2.7. Russia
                12.2.8. Poland
                12.2.9. Rest of Western Europe
          12.3 Market Size (US$ Mn) Forecast for Europe 2022-2028

13. Asia Pacific Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
          13.1 Introduction
          13.2 Historical Market Size (USD Mn) Analysis By Country, 2016-2020
                 13.2.1 Japan
                 13.2.2 China
                 13.2.3 Singapore
                 13.2.4 Korea         
                 13.2.5 India
                 13.2.6 Australia and New Zealand
                 13.2.7 ASEAN
                 13.2.8 Rest of Asia Pacific
          13.3 Market Size (US$ Mn) Forecast for Asia Pacific 2022-2028

14. Middle East and Africa Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
          14.1 Introduction
          14.2 Historical Market Size (USD Mn) Analysis By Country, 2016-2020
              14.2.1 UAE
              14.2.2 South Africa
              14.2.3 Egypt
              14.2.4 Saudi Arabia
              14.2.5 Rest of MEA
          14.3 Market Size (US$ Mn) Forecast for MEA 2022-2028

15. Market Share Analysis and Competitive Landscape   
          15.1. Global Landscape - Key Players, Revenue and Presence
          15.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
          15.3. Global Emerging Companies
          15.4. North America - Market Share Analysis and Key Regional Players
          15.5. Europe - Market Share Analysis and Key Regional Players
          15.6. Asia Pacific - Market Share Analysis and Key Regional Players
          15.7. Global Key Player - Growth Matrix

16. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Type and Technology Portfolio, Financial Layouts)
    16.1 Biogen
            16.1.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.1.2. Product Portfolio
            16.1.3. SWOT Analysis
            16.1.4. Financial Overview
            16.1.5. Strategic Overview
    16.2 Ionis Pharmaceuticals Inc.
            16.2.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.2.2. Product Portfolio
            16.2.3. SWOT Analysis
            16.2.4. Financial Overview
            16.2.5. Strategic Overview
    16.3 F. Hoffmann La Roche Ltd.
            16.3.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.2. Product Portfolio
            16.3.3. SWOT Analysis
            16.3.4. Financial Overview
            16.3.5. Strategic Overview
    16.4 Avenis Inc.
            16.4.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.4.2. Product Portfolio
            16.4.3. SWOT Analysis
            16.4.4. Financial Overview
            16.4.5. Strategic Overview
    16.5 Novartis AG
            16.5.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.5.2. Product Portfolio
            16.5.3. SWOT Analysis
            16.5.4. Financial Overview
            16.5.5. Strategic Overview
    16.6 Cytokinetics Inc.
            16.6.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.6.2. Product Portfolio
            16.6.3. SWOT Analysis
            16.6.4. Financial Overview
            16.6.5. Strategic Overview

17. Pre and Post COVID-19 Impact
    17.1. Positive influence on the healthcare industry
    17.2. The financial disruption of the manufacturing sector
    17.3. Impact of COVID-19 on emerging companies
    17.4. Significant mandates in the healthcare regulations initiated by administrations
    17.5. The overall economic slowdown of the developing and developed nations

18. FutureWise SME Key Takeaway Points for Client

Tables

Figures